Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CNBX Pharmaceuticals Inc.

Get SEC filing alerts via email and in your feed for CNBX Pharmaceuticals Inc.

CNBX

CNBX Pharmaceuticals Inc.

About CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc. is a clinical-stage biotech company developing cannabinoid-based therapies for cancer treatment, focusing on products like Cannabics SR for cancer cachexia and RCC-33 for colorectal cancer. It advances drug discovery, IP protection, and regulatory pathways, aiming for FDA approval and strategic licensing. The company emphasizes innovative formulations, preclinical and clinical trials, and partnerships, targeting unmet medical needs in oncology with a competitive edge in cannabinoid research.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CNBX Pharmaceuticals Inc.

1
1
CNBX Pharmaceuticals Inc. CNBX Pharmaceuticals Reports Q2 Fiscal 2026 Financial Results with $44K Net Loss

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
CNBX Pharmaceuticals Inc. CNBX Pharmaceuticals Reports Increased Net Loss and Declining Cash Reserves

Via official filing (AI summary) | 5 months ago | 0 comments

3
1
CNBX Pharmaceuticals Inc. CNBX Pharmaceuticals Reports No Revenue and Significant Losses for Fiscal Year Ending August 31, 2025

Via official filing (AI summary) | 6 months ago | 0 comments

4
1
CNBX Pharmaceuticals Inc. CNBX Pharmaceuticals Reports Zero Revenue and Significant Losses for Nine Months Ended May 31, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
CNBX Pharmaceuticals Inc. CNBX Pharmaceuticals Reports No Revenue and Improved Net Loss in Q2 FY 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CNBX Pharmaceuticals Inc. CNBX Pharmaceuticals Reports No Revenue and Reduced Net Loss for Quarter Ending November 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments